Cidara Therapeutics Inc

Cidara Therapeutics — Technical Presentation (December 2021)

24 slides from Cidara Therapeutics's technical presentation, Dec 14, 2021

  1. Slide 1: ReSTORE Phase 3 Trial Results for Rezafungin

    1 ReSTORE PHASE 3 TRIAL RESULTS FOR REZAFUNGIN L E A D I N G T H E S C I E N C E O F P R O T E C T I O N D e c 2 0 2 1

  2. Slide 2: Forward-Looking Statements

    2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words “believe,” “may,” “will,” “e

  3. Slide 3: Rezafungin Overall Phase 3 Development Plan

    3 R E Z A F U N G I N O V E R A L L P H A S E 3 D E V E LO P M E N T P L A N P H A S E 3 T R E AT M E N T T R I A L POTENTIAL INDICATION OVERALL OBJECTIVE Treatment of candidemia & invasive candidiasis FDA: Day 30 All-Cause Mortality vs SOC P H A S E 3 P R O P H Y L A X I S T R I A L Prophylaxis aga

  4. Slide 4: ReSTORE Phase 3 Trial Design

    4 Re S TO R E P H A S E 3 T R I A L D E S I G N 2 3 4 5 6 7 8 9 5 14 30 N= 93 Caspofungin Rezafungin N= 94 Week Day Week 1 2 3 4 5 6 7 8 9 Global Cure Global Cure (1° ENDPOINT – EMA) All-Cause Mortality (1° ENDPOINT – FDA) End of Follow Up Period 400/200mg Weekly 70/50mg Daily Dose Optional dose Dos

  5. Slide 5: ReSTORE Phase 3 Trial Results Summary

    5 Re S TO R E P H A S E 3 T R I A L R E S U LT S S U M M A RY P r i m a r y E f f i c a c y E n d p o i n t s S e c o n d a r y E f f i c a c y E n d p o i n t s E x p l o r a t o r y E f f i c a c y E n d p o i n t s S a f e t y • Both the FDA All-Cause Mortality at Day 30 as well as the EMA Global

  6. Slide 6: Key Baseline Demographics Similar Across Arms

    6 K E Y B A S E L I N E D E M O G R A P H I C S S I M I L A R A C R O S S A R M S DEMOGRAPHIC OR CHARACTERISTIC REZAFUNGIN n (%) CASPOFUNGIN n (%) Mean Age: ≥65 years 38 (40.9) 38 (40.4) Sex: Female 31 (33.3) 38 (40.4) Race Asian 23 (24.7) 31 (33.0) Black or African American 5 (5.4) 4 (4.3) White 59

  7. Slide 7: Day 30 All-Cause Mortality

    7 D AY 3 0 A L L - C A U S E M O R TA L I T Y ( P r i m a r y E n d p o i n t fo r F D A w a s A c h i e v e d ) A LL -C A U SE M O R TA LI TY D A Y 3 0 The upper limit of the 95% confidence interval for ACM is 14.4%, which is within the noninferiority margin of 20% established with the FDA. Rezafun

  8. Slide 8: Day 14 Global Cure

    8 60.6% 59.1% 0% 10% 20% 30% 40% 50% 60% 70% D AY 1 4 G LO B A L C U R E ( P r i m a r y E n d p o i n t fo r E M A w a s A c h i e v e d ) G LO B A L C U R E D A Y 1 4 The lower limit of the 95% confidence interval for Day 14 Global Cure is –14.9%, which is within the noninferiority margin of –20%

  9. Slide 9: Primary Endpoint Results by Subgroup

    9 P R I M A RY E N D P O I N T R E S U LT S BY S U B G R O U P A L L - C A U S E M O R T A L I T Y D A Y 3 0 G L O B A L C U R E D A Y 1 4 Day 30 All-Cause Mortality and Day 14 Global Cure were similar for rezafungin and caspofungin across these predefined subgroups. 51.9% 64.2% 55.2% 60.9% 30% 40%

  10. Slide 10: Global Cure at Day 5, Day 14, and Day 30

    10 G LO B A L C U R E AT D AY 5 , D AY 1 4 , A N D D AY 3 0 48.9% 60.6% 52.1% 49.5% 59.1% 55.9% 30% 40% 50% 60% 70% Global Cure Day 30 Global Cure Day 14 Global Cure Day 5 52/93 49/94 55/93 57/94 Rezafungin 400 mg/200 mg weekly (N=93) Caspofungin 70 mg/50 mg daily (N=94) Global Cures were similar be

  11. Slide 11: Mycological Eradication at Day 5, Day 14, and Day 30

    11 M YC O LO G I C A L E R A D I C AT I O N AT D AY 5 , D AY 1 4 , A N D D AY 3 0 D a y 5 , D a y 1 4 , a n d D a y 3 0 a r e S e c o n d a r y E n d p o i n t s , i n C a n d i d e m i a O n l y 59.7% 70.1% 68.7% 62.5% 71.9% 78.1% 50% 60% 70% 80% Mycological Eradication Day 30 Mycological Eradicati

  12. Slide 12: Early Efficacy and Median ICU Stay

    12 P H A S E 3 E A R LY E F F I C A C Y A N D M E D I A N I C U S TAY 0 7 14Day % Neg. Blood Culture1,2 % Mycological Eradication1 Rz Cf2 Rz CfRz Cf 36/67 1 DAY 5 DAYS2 DAYS 30/65 49/66 41/64 50/64 46/67 % Neg. Blood Culture1,2 53.7 46.2 78.1 68.7 74.2 64.1 n/N n/Nn/N 1. Patients with candidemia onl

  13. Slide 13: Early Efficacy and Median ICU Stay

    13 P H A S E 3 E A R LY E F F I C A C Y A N D M E D I A N I C U S TAY 0 7 14Day % Neg. Blood Culture1,2 % Mycological Eradication1 Rz Cf2 Rz CfRz Cf 36/67 1 DAY 5 DAYS2 DAYS 30/65 49/66 41/64 50/64 46/67 % Neg. Blood Culture1,2 53.7 46.2 78.1 68.7 74.2 64.1 n/N n/Nn/N 1. Patients with candidemia onl

  14. Slide 14: Rezafungin Phase 2 and Phase 3 All-Cause Mortality Results

    14 R E Z A F U N G I N P H A S E 2 A N D P H A S E 3 A L L - C AU S E M O R TA L I T Y R E S U LT S 21.3% 13.1% 23.7% 4.4% 15.8% 0% 10% 20% 30% All-Cause Mortality Day 30 All-Cause Mortality Day 30 12/76 8/61 2/46 22/93 20/94 P H A S E 2 P H A S E 3 Rezafungin 400 mg/200 mg weekly Caspofungin 70 mg/

  15. Slide 15: Rezafungin Phase 2 and Phase 3 Day 14 Cure Results

    15 R E Z A F U N G I N P H A S E 2 A N D P H A S E 3 D AY 1 4 C U R E R E S U LT S 60.6% 67.2% 59.1% 76.1% 60.5% 50% 60% 70% 80% 90% Global Cure Day 14 Overall Cure Day 14 46/76 41/61 35/46 55/93 57/94 P H A S E 2 1 P H A S E 3 2 Rezafungin 400 mg/200 mg weekly Caspofungin 70 mg/50 mg daily Rezafung

  16. Slide 16: Safety: Summary of Adverse Events

    16 Number of Subjects REZAFUNGIN 400 mg/200 mg Weekly N=98 n (%) CASPOFUNGIN 70 mg/50 mg Daily N=98 n (%) ≥1 TEAE 89 (90.8) 83 (84.7) Study drug-related* 16 (16.3) 9 (9.2) Serious AE 55 (56.1) 52 (53.1) Study drug-related* 2 (2.0) 3 (3.1) AE leading to study drug discontinuation 13 (13.3) 11 (11.2)

  17. Slide 17: Safety: Related Serious Adverse Events

    17 S A F E T Y: R E L AT E D S E R I O U S A D V E R S E E V E N T S A S D E T E R M I N E D BY T H E P I s • Rezafungin arm o Infusion-related reaction (Day 3) - Hypersensitivity reaction during the Day 3 infusion of saline placebo o Urticaria (Day 15) - Urticarial rash following oral placebo admin

  18. Slide 18: ReSTORE Phase 3 Trial Results Summary

    18 Re S TO R E P H A S E 3 T R I A L R E S U LT S S U M M A RY P r i m a r y E f f i c a c y E n d p o i n t s S e c o n d a r y E f f i c a c y E n d p o i n t s E x p l o r a t o r y E f f i c a c y E n d p o i n t s S a f e t y • Both the FDA All-Cause Mortality at Day 30 as well as the EMA Globa

  19. Slide 19: ReSTORE Provides Excellent Foundation for Commercialization

    19 REZAFUNGIN • No new treatments for IC in 15 years • NDA and EMA Filing expected mid-2022 • Go-to-market strategy optionality while preparing • Highly efficient market • Supply chain in place and launch supplies on hand • Fast Track, QIDP, Orphan designation for C/IC • Validated by Mundipharma par

  20. Slide 20: ReSTORE Provides Excellent Foundation for Commercialization

    20 R e S TO R E P R O V I D E S E XC E L L E N T F O U N D AT I O N F O R C O M M E R C I A L I Z AT I O N  Only drug in development successfully compared head-to-head in Ph3 with standard of care echinocandin in 1st line Candida treatment  1st and only once-weekly antifungal candidate  High fron

  21. Slide 21: ReSTORE Data and Market Input Define Clear Patient Opportunities

    21 R e S TO R E D ATA A N D M A R K E T I N P U T D E F I N E C L E A R PAT I E N T O P P O R T U N I T I E S 1. 30% of patients with Candida receive therapy for documented disease whereas 70% receive empiric therapy only (Internal estimate). 2. 30% of patients who start on an echinocandin are still

  22. Slide 22: Rezafungin: Two Phase 3 Programs vs Standards of Care

    22 Rezafungin is the only antifungal in clinical stage development for both 1st-line treatment and prophylaxis... …Fluconazole and voriconazole, which sold $1B and $800M at peak1,2 respectively, had a similar approach R E Z A F U N G I N : T W O P H A S E 3 P R O G R A M S V S S TA N D A R D S O F C

  23. Slide 23: Questions

    23 QUESTIONS L E A D I N G T H E S C I E N C E O F P R O T E C T I O N D e c 2 0 2 1

  24. Slide 24: Thank You

    24 THANK YOU L E A D I N G T H E S C I E N C E O F P R O T E C T I O N D e c 2 0 2 1

Cidara Therapeutics — Technical Presentation (December 2021) on 6ix